Industry Symposium
Is there a place for BCMA-based combinations in early RRMM?
25 May 2024, 9:20-10:50 CEST
FACULTY
Sagar Lonial, MD (Co-chair)
Professor, Chair, and Chief Medical Officer
Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, GA, USA
Hermann Einsele, MD (Co-chair)
Professor and Chair
Department of Internal Medicine
University of Würzburg
Würzburg, Germany
Rakesh Popat, MD, PhD
Consultant Hematologist and Associate Professor
University College Hospital
London, UK
Hang Quach, MD
Professor/Director of Clinical Hematology Medicine
St Vincent’s Hospital, University of Melbourne
Melbourne, Australia
| AGENDA | |
|---|---|
| 25 min |
Welcome and faculty introduction Sagar Lonial, MD Presentation 1: State of the art data review: novel regimens for the potential treatment of patients with early RRMM Sagar Lonial, MD Panel and audience discussion 1 (with Q&A): Are the goals of therapy at first MM relapse changing given the rapidly transforming treatment landscape and recent data read-outs? All faculty, moderated by Hermann Einsele, MD |
| 25 min |
Presentation 2: Perspectives on the real-world management of patients with RRMM Rakesh Popat, MD, PhD Panel and audience discussion 2 (with Q&A): How can we evolve real-world strategies for optimizing the benefit-risk for patients in earlier lines of therapy? All faculty, moderated by Sagar Lonial, MD |
| 25 min |
Presentation 3: Options overload: the many treatment choices currently available for second-line patients with MM Hang Quach, MD Panel and audience discussion 3 (with Q&A): Is there a true unmet need for novel options for patients experiencing their first MM relapse? All faculty, moderated by Hermann Einsele, MD |
| 10 min |
Audience Q&A All faculty, moderated by Sagar Lonial, MD, and Hermann Einsele, MD |
| 5 min |
Closing remarks Hermann Einsele, MD |